Latest Regulatory News

IRIS Metals has agreed to sell its Kookynie Gold Project to Arika Resources, securing cash and equity to fuel its lithium ambitions in the US. This strategic move realigns IRIS’s portfolio towards critical minerals while retaining exposure to Kookynie through Arika shares.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

RPM Automotive Group Ltd reported steady FY25 results with improved margins despite a slight revenue dip, while outlining strategic growth and tyre recycling expansion plans for FY26.

Cosmos Exploration’s optioned entity, EAU Lithium, has agreed to acquire a fully constructed pilot plant from Vulcan Energy Resources to advance lithium extraction testing in Bolivia. This move strengthens Cosmos’ strategic foothold in one of the world’s most promising lithium regions.

Westgold Resources Limited has announced an on-market buy-back of up to 47.18 million shares, signaling a strategic move to manage capital and potentially boost shareholder value.

Ramsay Health Care has confirmed the payment of a fully franked ordinary dividend on its perpetual preference securities, clearing prior approval conditions and setting a payment date for October 2025.

Shine Justice Ltd reported a 4.4% rise in FY25 revenue to $204.4 million, alongside major legal settlements and leadership changes, signaling renewed growth momentum.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.

Westgold Resources Limited has announced a 3 cent per share final dividend for the financial year ending June 2025, payable in October. The dividend is unfranked, reflecting the company’s current tax position.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.